Dopaminergic Modulation of Dynamic Emotion Perception.
cognition
dopamine
emotion
psychopharmacology
temporal processing
working memory
Journal
The Journal of neuroscience : the official journal of the Society for Neuroscience
ISSN: 1529-2401
Titre abrégé: J Neurosci
Pays: United States
ID NLM: 8102140
Informations de publication
Date de publication:
25 05 2022
25 05 2022
Historique:
received:
30
11
2021
revised:
20
03
2022
accepted:
22
03
2022
pubmed:
3
5
2022
medline:
28
5
2022
entrez:
2
5
2022
Statut:
ppublish
Résumé
Emotion recognition abilities are fundamental to our everyday social interaction. A large number of clinical populations show impairments in this domain, with emotion recognition atypicalities being particularly prevalent among disorders exhibiting a dopamine system disruption (e.g., Parkinson's disease). Although this suggests a role for dopamine in emotion recognition, studies employing dopamine manipulation in healthy volunteers have exhibited mixed neural findings and no behavioral modulation. Interestingly, while a dependence of dopaminergic drug effects on individual baseline dopamine function has been well established in other cognitive domains, the emotion recognition literature so far has failed to account for these possible interindividual differences. The present within-subjects study therefore tested the effects of the dopamine D2 antagonist haloperidol on emotion recognition from dynamic, whole-body stimuli while accounting for interindividual differences in baseline dopamine. A total of 33 healthy male and female adults rated emotional point-light walkers (PLWs) once after ingestion of 2.5 mg haloperidol and once after placebo. To evaluate potential mechanistic pathways of the dopaminergic modulation of emotion recognition, participants also performed motoric and counting-based indices of temporal processing. Confirming our hypotheses, effects of haloperidol on emotion recognition depended on baseline dopamine function, where individuals with low baseline dopamine showed enhanced, and those with high baseline dopamine decreased emotion recognition. Drug effects on emotion recognition were related to drug effects on movement-based and explicit timing mechanisms, indicating possible mediating effects of temporal processing. Results highlight the need for future studies to account for baseline dopamine and suggest putative mechanisms underlying the dopaminergic modulation of emotion recognition.
Identifiants
pubmed: 35501156
pii: JNEUROSCI.2364-21.2022
doi: 10.1523/JNEUROSCI.2364-21.2022
pmc: PMC9145228
doi:
Substances chimiques
Dopamine D2 Receptor Antagonists
0
Haloperidol
J6292F8L3D
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4394-4400Informations de copyright
Copyright © 2022 the authors.
Références
Hum Mov Sci. 2018 Feb;57:478-488
pubmed: 29174557
Emotion. 2021 Aug;21(5):1041-1061
pubmed: 33661668
Neuroimage. 2005 Oct 1;27(4):991-1001
pubmed: 15978846
Biol Psychiatry. 2011 Jun 15;69(12):e113-25
pubmed: 21531388
Cogn Affect Behav Neurosci. 2001 Jun;1(2):137-60
pubmed: 12467110
Cereb Cortex. 2009 Feb;19(2):445-54
pubmed: 18550595
Psychol Sci. 2001 Jan;12(1):18-23
pubmed: 11294223
J Exp Psychol Hum Percept Perform. 2020 Jul;46(7):657-666
pubmed: 32584128
J Speech Lang Hear Res. 2019 May 21;62(5):1225-1242
pubmed: 31082309
Neuroscientist. 2021 Feb;27(1):30-46
pubmed: 32338128
Neural Comput. 2006 Feb;18(2):283-328
pubmed: 16378516
Neuroreport. 1997 Nov 10;8(16):3581-5
pubmed: 9427330
Clin Pharmacokinet. 1999 Dec;37(6):435-56
pubmed: 10628896
Psychosom Med. 2009 Jun;71(5):580-7
pubmed: 19414617
J Neurosci. 2012 Nov 21;32(47):16704-15
pubmed: 23175824
J Neurosci. 2001 Dec 1;21(23):9134-41
pubmed: 11717346
Clin Neuropharmacol. 2005 Nov-Dec;28(6):255-61
pubmed: 16340378
Mov Disord. 2018 Apr;33(4):554-567
pubmed: 29473661
Neuroreport. 2002 May 7;13(6):881-4
pubmed: 11997706
J Cogn Neurosci. 2016 Jan;28(1):96-110
pubmed: 26401816
Neuron. 2010 Dec 9;68(5):815-34
pubmed: 21144997
J Mem Lang. 2013 Apr;68(3):
pubmed: 24403724
Psychopharmacology (Berl). 2021 Dec;238(12):3569-3584
pubmed: 34676440
J Exp Psychol Hum Percept Perform. 2017 Jul;43(7):1263-1268
pubmed: 28639823
PLoS One. 2012;7(9):e44473
pubmed: 22970227
Nature. 1995 Aug 17;376(6541):572-5
pubmed: 7637804
Cogn Affect Behav Neurosci. 2005 Jun;5(2):212-21
pubmed: 16180627
Neuropsychopharmacology. 1996 Jul;15(1):53-61
pubmed: 8797192
J Cogn Neurosci. 2005 Jan;17(1):51-72
pubmed: 15701239
J Neurochem. 2003 Oct;87(2):273-89
pubmed: 14511105
Psychopharmacology (Berl). 2007 Apr;191(3):507-20
pubmed: 17031711
Behav Neurosci. 2006 Jun;120(3):497-517
pubmed: 16768602
Clin Psychol Rev. 2002 Jul;22(6):789-832
pubmed: 12214327
Philos Trans R Soc Lond B Biol Sci. 2014 Apr 28;369(1644):20130490
pubmed: 24778386
Hum Mov Sci. 2012 Feb;31(1):202-21
pubmed: 21835480
Neuropsychopharmacology. 2002 Dec;27(6):1036-40
pubmed: 12464460
Science. 1966 Aug 5;153(3736):652-4
pubmed: 5939936
Neuroimage. 2000 Sep;12(3):268-75
pubmed: 10944409
J Clin Psychopharmacol. 2007 Dec;27(6):692-7
pubmed: 18004139
Trends Cogn Sci. 2021 Nov;25(11):950-963
pubmed: 34531138
Psychol Rev. 2006 Apr;113(2):300-326
pubmed: 16637763
Neurosci Biobehav Rev. 2012 Jan;36(1):237-53
pubmed: 21699916
J Neurosci. 2008 Jan 30;28(5):1208-12
pubmed: 18234898
J Vis. 2009 Jun 26;9(6):15.1-32
pubmed: 19761306